Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Panel Advice In, FDA To Conclude Menaflex 510(k) Re-Review In Weeks

This article was originally published in The Gray Sheet

Executive Summary

FDA will announce the outcome of its re-review of ReGen Biologic's 510(k)-cleared Menaflex knee repair device "in the coming weeks," CDRH Director Jeffrey Shuren said last week
Advertisement

Related Content

FDA To Rescind A 510(k): Rare Action Targets ReGen's Menaflex Device
FDA To Rescind A 510(k): Rare Action Targets ReGen's Menaflex Device
FDA To Rescind A 510(k): Rare Action Targets ReGen's Menaflex Device
CMS denies coverage for Menaflex
CMS denies coverage for Menaflex
FDA Questions Data Supporting ReGen's Menaflex Ahead Of 510(k) Re-Review
FDA Questions Data Supporting ReGen's Menaflex Ahead Of 510(k) Re-Review
Internal FDA Menaflex Investigation Finds Serious Process Deviations

Topics

Advertisement
UsernamePublicRestriction

Register

MT028683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel